Alps Advisors Inc. Trims Stake in Eli Lilly And Co (NYSE:LLY) – Polson News

Alps Advisors Inc. reduced its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 31.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,138 shares of the companys stock after selling 10,377 shares during the period. Alps Advisors Inc.s holdings in Eli Lilly And Co were worth $2,476,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Selective Wealth Management Inc. purchased a new stake in shares of Eli Lilly And Co in the third quarter worth $25,000. Enterprise Trust & Investment Co purchased a new stake in shares of Eli Lilly And Co in the third quarter worth $27,000. Garrett Wealth Advisory Group LLC purchased a new stake in shares of Eli Lilly And Co in the third quarter worth $29,000. Quest Capital Management Inc. ADV purchased a new stake in shares of Eli Lilly And Co in the third quarter worth $34,000. Finally, Prestige Wealth Management Group LLC purchased a new stake in shares of Eli Lilly And Co in the second quarter worth $34,000. 77.22% of the stock is owned by institutional investors and hedge funds.

A number of analysts have recently issued reports on LLY shares. Bank of America started coverage on shares of Eli Lilly And Co in a research note on Wednesday, October 16th. They issued a buy rating and a $133.00 price objective for the company. UBS Group reduced their price objective on shares of Eli Lilly And Co from $134.00 to $133.00 and set a buy rating for the company in a research note on Thursday, October 17th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $130.03.

Shares of Eli Lilly And Co stock opened at $113.53 on Friday. The firms 50 day moving average price is $110.61 and its 200-day moving average price is $112.67. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 4.09. Eli Lilly And Co has a 52-week low of $101.36 and a 52-week high of $132.13. The company has a market cap of $106.81 billion, a P/E ratio of 20.46, a PEG ratio of 1.82 and a beta of 0.16.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts consensus estimates of $1.43 by $0.05. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The firm had revenue of $5.48 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter in the previous year, the firm earned $1.39 EPS. The companys quarterly revenue was up 3.2% compared to the same quarter last year. As a group, equities research analysts forecast that Eli Lilly And Co will post 5.78 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $0.645 dividend. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.27%. The ex-dividend date is Thursday, November 14th. Eli Lilly And Cos payout ratio is currently 46.49%.

In related news, major shareholder Lilly Endowment Inc sold 173,918 shares of Eli Lilly And Co stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $114.05, for a total value of $19,835,347.90. Following the completion of the sale, the insider now directly owns 116,229,383 shares in the company, valued at approximately $13,255,961,131.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 4,500 shares of Eli Lilly And Co stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $117.00, for a total transaction of $526,500.00. Following the completion of the sale, the senior vice president now owns 33,806 shares of the companys stock, valued at $3,955,302. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 8,405 shares of company stock valued at $909,004 and sold 614,373 shares valued at $70,546,895. 0.11% of the stock is owned by company insiders.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Is it Safe to Invest in Commodities?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Read the original post:
Alps Advisors Inc. Trims Stake in Eli Lilly And Co (NYSE:LLY) - Polson News